Deutsche Bank Appointed as Depositary Bank for the NASDAQ-Listed Sponsored Level III American Depositary Receipt Program of Midatech Pharma PLC

NEW YORK & LONDON--(BUSINESS WIRE)-- Deutsche Bank today announced its appointment as sponsored depositary bank for the Level III NASDAQ-listed American Depositary Receipt (ADR) program of Midatech Pharma PLC (Midatech).

Midatech (NASDAQ: MTP) is a specialty pharmaceutical company focused on the development and commercialization of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with unmet medical need. These diseases include diabetes, certain cancers such as liver, pancreatic, ovarian and brain (glioblastoma), and neurological/ophthalmologic conditions. As of and for the six months ended June 30, 2015, Midatech had total assets of GPB 42.3 million, total revenues of GPB 324,000, total liabilities of GPB 5.1 million, and total equity of GPB 37.1 million. Headquartered in Oxfordshire, England, Midatech’s ordinary shares are quoted on the AIM Market of the London Stock Exchange plc under the symbol “MTPH”.*

“We are delighted to be appointed as the sponsored depositary bank for Midatech Pharma PLC’s NASDAQ-listed ADR program,” said Jose Sicilia, Head of Depositary Receipts, Institutional Cash & Securities Services. “Deutsche Bank will deploy its broad range of customized services to assist Midatech Pharma PLC in enhancing the visibility of its ADR program with the investor community.”

Deutsche Bank’s Depositary Receipts team is part of the Issuer Services business within the Bank’s Institutional Cash & Securities Services unit. In addition to specializing in administering cross-border equity structures such as American and global depositary receipts and global registered shares, Issuer Services provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

*Source: Midatech Pharma PLC (December 2015)

Deutsche Bank is a leading client-centric global universal bank serving 28 million clients worldwide. Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© December 2015 Deutsche Bank AG. All rights reserved.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151207005997/en/

Deutsche Bank AG
Press & Media Relations
Hannah Fuchs, +1-212-250-4070
[email protected]

Source: Deutsche Bank

You May Also Be Interested In

• Deutsche Bank Upgrades Medical Properties Trust (MPW) to Hold, 'Debt Maturity Likely Resolved Until At Least 2025'
• Notification in accordance with Chapter 9, section 5, of the Securities Markets Act
• ICE Announces Record Trading Activity in Murban Crude as ICE Futures Abu Dhabi Marks Third Anniversary